Basal levels of sex steroids, and the responses of LH and FSH to LH-RH were studied in twenty-five female patients with Cushing's syndrome (17 Cushing's disease and 8 adrenocortical adenoma). Only two patients had a regular menstrual cycle. Amenorrhea or oligomenorrhea had been of long duration in the other cases except for three postmenopausal patients. In patients with Cushing's disease, basal estradiol was low or below normal in 86%. Progesterone was normal in 83%, but testosterone was high in half of the cases. The response of LH to LH-RH in patients with Cushing's disease was normal in 35%, low in 35% and high in 29% of the cases. FSH response to LH-RH was normal in 23.5%, low in 23.5% and high in 53%. In patients with adrenocortical adenoma, basal of estradiol was low or below normal, but progesterone and testosterone were normal in all cases. The response of LH and FSH to LH-RH in all patients with adrenocortical adenoma was higher than normal. In three postmenopausal women, a higher response of LH and FSH to LH-RH was seen in two cases and suppressed in one case. These data suggest that the main site of suppression of the gonadal axis in patients with adrenocortical adenoma is the gonad rather than the pituitary gland or hypothalamus, though the mechanism of hypogonadism in patients with Cushing's disease is heterogeneous.
Hypogonadism is a common symptome in patients with Cushing's syndrome. Although disturbance of the central nervous system is considered in these patients, it is thought that hypercortisolism might affect inhibition of the hypothalamo-pituitarygonadal axis. However, little is known about the mechanism by which this axis is suppressed by glucocorticoids (GC). As to the site of action of GC on this axis, three sites, the hypothalamus, pituitary gland and gonad are considered.
From the weak response of gonadotropins to LH-RH in patients with Cushing's disease (Boccuzzi et al., 1975) and in those receiving long term treatment with GC (Sakakura et al., 1975) , the pituitary and/or hypothalamus have been considered as primary sites of GC action. However, Suter et al. (1985) reported that the suppressive effect of GC was exerted only on LH secretion, and GC rather increased FSH release in primary pituitary cell cultures of female rat. It has been reported that the GC inhibits steroidgenesis in the ovary (Hsueh et al., 1978) and testis (Welsh et al., 1982) . Thus the sites of GC action on the gonadal axis are still controversial.
In this study, we investigated gonadal steroids, and LH and FSH response to LH-RH in patients with Cushing's syndrome.
Materials
and Methods Patients' profiles and levels of various hormones in the plasma and urine are summarized in Table 1 . Amenorrhea had lasted from 2 months to five years in sixteen patients with Cushing's syndrome. Five patients had oligmenorrhea, and patient No. 15 aged 15 years, was of short stature and had primary amenorrhea. Three patients were postmenopausal.
There was no correlation between the duration of amenorrhea and the amount of cortisol in plasma and urine. Neither basal nor peak levels of gonadotropins by LH-RH had any correlation with sex steroid hormones. Fig. 1 shows the gonadal steroids in plasma. In patients with Cushing's disease (closed circle), the basal concentration of estradiol was low in 8/14 (57.1%) and subnormal in 4/14 (28.6%). One patient showing a higher concentration of estradiol had a regular menstrual cycle. Progesterone was almost normal in all except two of the patients with Cushing's disease. Testosterone was high in 8/17 (47.1%), normal in 7/17 (41.2%) and low in 2 cases. All cases due to adrenocortical adenoma (open circle) had low or low normal estradiol. Progesterone and testosterone were within normal limits in all cases with adrenocortical adenoma. The response of LH and FSH to LH-RH is shown in Fig. 2 . In patients with Cushing's disease, LH response to LH-RH was low in 6/17 (35.3%), normal in 6/17 (35.3%) and high in 5/17 (29.4%).
FSH response to LH-RH in patients with Cushing's disease was low in 4/17 (23.5%), normal in 4/17 (23.5%) and high in 9/17 (52.9%). In all patients with adrenocortical adrenoma, the response LH, as well as FSH to LH-RH, was higher than normal. The response of LH and FSH was not suppressed in two duction and the activity of 17a-hydroxylase. The source of plasma testosterone in Cushing's syndrome is thought to be secretion from the adrenal gland, and high concentrations of plasma testosterone were detected in our patients. GC might contribute to an increase in plasma testosterone by interfering with the action of various enzymes, especially aromatase in the ovary. In addition to enzyme blockage, GC are known to regulate steroidgenesis by decreasing HCG/LH receptors in the testis (Bambino et al., 1981) . These data were obtained in in vitro studies on the basis of animal experiments. There are few reports which show the effects of GC on the gonad in human subjects. If GC suppress only gonadal steroidgenesis, not only the basal concentration but also the response of gonadotropins to LH-RH should be higher. In our study, gonadotropin response to LH-RH was relatively weak in comparison with the low level of of estrogen. The response of LH to LH-RH was shown to be reduced (Boccuzzi et al., 1975) or normal (Demura et al., 1972) in patients with Cushing's disease. Buccuzi et al. (1975) suggested that endogeneous hypercortisolism might play impair the response of LH-RH in patients with Cushing's disease. In view of the suppressed response of LH to LH-RH in patients receiving chronic administration of predonisolone, Sakakura et al. (1975) also suggested that GC alters pituitary responsiveness to exogeneous LH-RH by acting either directly or indirectly on the pituitary gland and/or hypothalamus. Five patients, including one postmenopausal woman, showed low response of LH to LH-RH in our study. Nevertheless, two cases with postmenopause showed no suppression of LH or FSH to LH-RH. These data indicate that, in patients with Cushing's syndrome, there are hypothalamo-pituitary sites of suppression by GC in addition to the gonad. In addition to GC suppression of this axis, an excess production of androgen might suppress LH release. However, the basal secretion of LH was somewhat higher in patients with high testosterone in our study. In contrast to reduced response of LH, FSH response was relatively well maintained. Boccuzi et al. (1975) reported that FSH response to LH-RH was normal, even though LH release was suppressed. Baldwin (1979) suggested that GC has a different effect on LH-and FSH-secreting cells, as LH secretion was suppressed, while pituitary content and the release of FSH are increased by GC treatment in pituitary primary culture. These data suggest that the regulatory mechanism of LH and FSH might be different.
In our study, the response of LH and FSH to LH-RH in patients with Cushing's disease was heterogeneous. However, LH and FSH response in patients with adrenocortical adenoma was stronger than normal. Numerous studies have suggested opiateinduced suppression of gonadotropin secretion in animals (Bruni et al., 1977; Matteri et al., 1985) and human subjects (Snowden et al., 1984; Reid et al., 1981) . Thus, increased endogenous opiate might modulate gonadotropin secretion in patients with Cushing's disease.
In addition, a change in the central mechanism, resulting in interferes with the regulation of hormones in the pituitary and hypothalamus, might contribute to gonadotropin response to LH-RH.
